A Comparison of the Effectiveness, Safety, and Tolerability of Two Different Hepatitis C Treatments in Patients Infected With Both HIV and Hepatitis C Virus (HCV)

PHASE2CompletedINTERVENTIONAL
Enrollment

132

Participants

Timeline

Start Date

November 30, 2000

Study Completion Date

August 31, 2006

Conditions
HIV InfectionsHepatitis C
Interventions
DRUG

Ribavirin

DRUG

Interferon alfa-2a

DRUG

Peginterferon alfa-2a

Trial Locations (24)

10003

Beth Israel Med. Ctr., ACTU, New York

10016

NY Univ. HIV/AIDS CRS, New York

10029

Mt. Sinai Med. Ctr. A0404 CRS, New York

14642

AIDS Care CRS, Rochester

Univ. of Rochester ACTG CRS, Rochester

19104

Philadelphia Veterans Admin. Med. Ctr. A6205 CRS, Philadelphia

30308

The Ponce de Leon Ctr. CRS, Atlanta

46202

Indiana Univ. School of Medicine, Wishard Memorial, Indianapolis

Methodist Hosp. of Indiana, Indianapolis

52242

Univ. of Iowa Healthcare, Div. of Infectious Diseases, Iowa City

55455

University of Minnesota, ACTU, Minneapolis

75390

Univ. of Texas Southwestern Med. Ctr., Amelia Court Continuity Clinic, Dallas

80262

University of Colorado Hospital CRS, Aurora

92103

Ucsd, Avrc Crs, San Diego

96816

Univ. of Hawaii at Manoa, Leahi Hosp., Honolulu

331361013

Univ. of Miami AIDS CRS, Miami

452670405

Univ. of Cincinnati CRS, Cincinnati

462025250

Indiana Univ. School of Medicine, Infectious Disease Research Clinic, Indianapolis

941104206

Ucsf Aids Crs, San Francisco

02114

Massachusetts General Hospital ACTG CRS, Boston

02118

Bmc Actg Crs, Boston

02215

Beth Israel Deaconess Med. Ctr., ACTG CRS, Boston

Brigham and Women's Hosp. ACTG CRS, Boston

Unknown

HIV Prevention & Treatment CRS, New York

All Listed Sponsors
lead

National Institute of Allergy and Infectious Diseases (NIAID)

NIH

NCT00008463 - A Comparison of the Effectiveness, Safety, and Tolerability of Two Different Hepatitis C Treatments in Patients Infected With Both HIV and Hepatitis C Virus (HCV) | Biotech Hunter | Biotech Hunter